102
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Extracellular Matrix-Associated Pathways Promote the Progression of Gastric Cancer by Impacting the Dendritic Cell Axis

, , , , &
Pages 6725-6739 | Published online: 13 Oct 2021

References

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
  • Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
  • Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18(3):534–542. doi:10.1016/j.cgh.2019.07.045
  • Zheng P, Chen L, Yuan X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017;36(1):53. doi:10.1186/s13046-017-0528-y
  • Wei L, Sun J, Zhang N, et al. Noncoding RNAs in gastric cancer: implications for drug resistance. Mol Cancer. 2020;19(1):62. doi:10.1186/s12943-020-01185-7
  • Yeon M, Kim Y, Pathak D, et al. The CAGE-MiR-181b-5p-S1PR1 axis regulates anticancer drug resistance and autophagy in gastric cancer cells. Front Cell Dev Biol. 2021;9:666387. doi:10.3389/fcell.2021.666387
  • Wang J, Lv B, Su Y, Wang X, Bu J, Yao L. Exosome-mediated transfer of lncRNA HOTTIP promotes cisplatin resistance in gastric cancer cells by regulating HMGA1/miR-218 axis. Onco Targets Ther. 2019;12:11325–11338. doi:10.2147/OTT.S231846
  • Wang Q, Liang J, Hu X, Gu S, Xu Q, Yan J. Early B cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer. Biosci Rep. 2021;41(7). doi:10.1042/BSR20210055
  • Li L, Wang X. Identification of gastric cancer subtypes based on pathway clustering. NPJ Precis Oncol. 2021;5(1):1–17. doi:10.1038/s41698-021-00186-z
  • Lu X, Jiang L, Zhang L, et al. Immune signature-based subtypes of cervical squamous cell carcinoma tightly associated with human papillomavirus type 16 expression, molecular features, and clinical outcome. Neoplasia. 2019;21(6):591–601. doi:10.1016/j.neo.2019.04.003
  • Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the Phase II IMvigor210 study. Ann Oncol. 2017;28(12):3044–3050. doi:10.1093/annonc/mdx518
  • Meng J, Zhou Y, Lu X, et al. Immune response drives outcomes in prostate cancer: implications for immunotherapy. Mol Oncol. 2020. doi:10.1002/1878-0261.12887
  • Roh W, Chen PL, Reuben A, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9(379):eaah3560. doi:10.1126/scitranslmed.aah3560
  • Heagerty PJ, Lumley T, Pepe MS. Time‐dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–344. doi:10.1111/j.0006-341X.2000.00337.x
  • Liao AP, Salajegheh M, Morehouse C, et al. Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production. Clin Immunol. 2010;136(1):130–138. doi:10.1016/j.clim.2010.02.014
  • Wimmers F, Subedi N, van Buuringen N, et al. Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells. Nat Commun. 2018;9(1):3317. doi:10.1038/s41467-018-05784-3
  • Socovich AM, Naba A. The cancer matrisome: from comprehensive characterization to biomarker discovery. Semin Cell Dev Biol. 2019;89:157–166. doi:10.1016/j.semcdb.2018.06.005
  • Naba A, Clauser KR, Ding H, Whittaker CA, Carr SA, Hynes RO. The extracellular matrix: tools and insights for the “omics” era. Matrix Biol. 2016;49:10–24. doi:10.1016/j.matbio.2015.06.003
  • Han S, Wang Z, Liu J, Wang HD, Yuan Q. miR-29a-3p-dependent COL3A1 and COL5A1 expression reduction assists sulforaphane to inhibit gastric cancer progression. Biochem Pharmacol. 2021;188:114539. doi:10.1016/j.bcp.2021.114539
  • Liu C, Deng L, Lin J, et al. Zinc finger protein CTCF regulates extracellular matrix (ECM)-related gene expression associated with the Wnt signaling pathway in gastric cancer. Front Oncol. 2020;10:625633. doi:10.3389/fonc.2020.625633
  • Wei Z, Chen L, Meng L, Han W, Huang L, Xu A. LncRNA HOTAIR promotes the growth and metastasis of gastric cancer by sponging miR-1277-5p and upregulating COL5A1. Gastric Cancer. 2020;23(6):1018–1032. doi:10.1007/s10120-020-01091-3
  • Zhao Y, Zhang J, Yang W, Yang Z, Zhou K. MicroRNA-552 accelerates the progression of gastric cancer by targeting FOXO1 and regulating PI3K/AKT pathway. J Oncol. 2021;2021:9966744. doi:10.1155/2021/9966744
  • Li H, Xu L, Zhao L, et al. Insulin-like growth factor-I induces epithelial to mesenchymal transition via GSK-3β and ZEB2 in the BGC-823 gastric cancer cell line. Oncol Lett. 2015;9(1):143–148. doi:10.3892/ol.2014.2687
  • Lu WD, Zuo Y, Xu Z, Zhang M. MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer. World J Gastroenterol. 2015;21(15):4564–4573. doi:10.3748/wjg.v21.i15.4564
  • Meng J, Guan Y, Wang Bet al. Molecular subtyping and prognostic assessment of prostate cancer based on consensus genes. Research Square. 2021. doi:10.21203/rs.3.rs-413181/v1
  • Sun J, Jiang Q, Chen H, et al. Genomic instability-associated lncRNA signature predicts prognosis and distinct immune landscape in gastric cancer. Ann Transl Med. 2021;9(16):1326. doi:10.21037/atm-21-3569
  • Chen T, Yang C, Dou R, Xiong B. Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer. Cancer Med. 2021;10(18):6546–6560. doi:10.1002/cam4.4180
  • Zhang C, Li D, Yu R, et al. Immune landscape of gastric carcinoma tumor microenvironment identifies a peritoneal relapse relevant immune signature. Front Immunol. 2021;12:651033. doi:10.3389/fimmu.2021.651033
  • Izumi D, Gao F, Toden S, et al. A genomewide transcriptomic approach identifies a novel gene expression signature for the detection of lymph node metastasis in patients with early stage gastric cancer. EBioMedicine. 2019;41:268–275. doi:10.1016/j.ebiom.2019.01.057
  • Li J, Pu K, Li C, Wang Y, Zhou Y. A novel six-gene-based prognostic model predicts survival and clinical risk score for gastric cancer. Front Genet. 2021;12:615834. doi:10.3389/fgene.2021.615834
  • Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. doi:10.1001/jamaoncol.2018.0013
  • Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2017;390(10111):2461–2471. doi:10.1016/S0140-6736(17)31827-5